Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Methods: In this prospective observational study, 45 patients with T2DM were divided into two groups according to pre-study dapagliflozin use: a dapagliflozin-nave group (Control group, n=22) and a dapagliflozin-exposed group (DAPA group, n=23)
These entrants are leveraging strengths in peptide synthesis, low-cost biologics manufacturing, and regulatory agility to shorten development cycles and undercut price points, potentially halving or even reducing cost to one-tenth of current therapy levels
Out of these 8, 1 trial is in PHASE4
GLP-1 therapies frequently cause nausea and vomiting, with diarrhea being another common complaint
In an embodiment, a composition is at least 90% purity tirzepatide after about 2 years at 5 degrees Celsius
US$ 29.76
US$ 25.17
US$ 28.57
